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3,4-dichloromethylphenidate (3,4-CTMP) and ethylphenidate are new psychoactive
substances and analogs of the attention deficit medication methylphenidate. Both drugs
have been reported on online user fora to induce effects similar to cocaine. In the
UK, 3,4-CTMP appeared on the drug market in 2013 and ethylphenidate has been
sold since 2010. We aimed to explore the neurochemical effects of these drugs on
brain dopamine and noradrenaline efflux. 3,4-CTMP and ethylphenidate, purchased from
online vendors, were analyzed using gas chromatography and mass spectroscopy to
confirm their identity. Drugs were then tested in adolescent male rat brain slices of
the nucleus accumbens and stria terminalis for effects on dopamine and noradrenaline
efflux respectively. Fast cyclic voltammetry was used to measure transmitter release.
Methylphenidate (10µM) increased evoked dopamine and noradrenaline efflux by
4- and 2-fold, respectively. 3,4-CTMP (0.1 and 1µM) increased evoked dopamine
and noradrenaline efflux by ∼6-fold and 2-fold, respectively. Ethylphenidate (1µM)
doubled evoked dopamine and noradrenaline efflux in both cases. 3,4-CTMP’s effect
on dopamine efflux was greater than that of methylphenidate, but ethylphenidate
appears to be a weaker dopamine transporter inhibitor. Experiments using the dopamine
D2 antagonist haloperidol, the noradrenaline α2 receptor antagonist yohimbine, the
dopamine transporter inhibitor GBR12909 and the noradrenaline transporter inhibitor
desipramine confirmed that we were measuring dopamine in the accumbens and
noradrenaline in the ventral BNST. All three psychostimulant drugs, through their effects
on dopamine efflux, may have addictive liability although the effect of 3,4-CTMP on
dopamine suggests that it might be most addictive and ethylphenidate least addictive.
Keywords: novel psychoactive substance, dopamine, noradrenaline, voltammetry, brain slice, adolescent
Davidson et al. Methylphenidate Analog Legal Highs
INTRODUCTION
Concern has arisen over the past few years about “legal highs” or
new psychoactive substances (NPS). Some of these NPS produce
similar effects to cocaine, amphetamine, or MDMA (Ecstasy)
and have changed the landscape of the UK drug scene by
offering drug users the opportunity to use drugs without the
risk of prosecution. The most prominent NPS is mephedrone,
which was banned in the UK in 2010. The number of legal
highs being sold on the Internet is increasing year-on-year.
Deluca et al. (1) carried out a European-wide web-mapping
project to quickly identify NPS use in Europe. By monitoring
drug fora and websites, which provide information on legal
highs between the drug communities, the authors uncovered
414 substances/products. The number of NPS discovered is now
thought to be closer to 1000 (EMCDDA).
Many of these NPS have been associated with emergency
room visits (2–4) and drug related deaths (5), it is therefore
important to learn about the pharmacology of these substances,
for which very little is known. We have recently identified 2 NPS
from samples obtained from London dance club amnesty bins
or samples purchased on the internet and examined these drugs,
3,4-CTMP and ethylphenidate, using neurochemical assays. 3,4-
CTMP is an NPS that became available for purchase on the
Internet in January 2013. Ethylphenidate is an NPS that has been
sold since 2010. Both drugs are closely related to the attention
deficit medication methylphenidate (Ritalin R©; Figure 1).
Drugs such as cocaine, amphetamine, and MDMA increase
dopamine concentration in the rodent nucleus accumbens (6,
7) making the accumbens an ideal location to investigate the
addictive liability of NPS. Imaging studies of the human brain
have also shown that increased dopamine levels in the striatum
as a result of drug use are associated with the euphoric effects of
drugs (8). The nucleus accumbens and bed nucleus of the stria
terminalis are both part of the extended amygdala (9), which is
thought to integrate brain arousal-stress systems with hedonic
processing systems. Stress induced reinstatement of some drugs
of abuse in animal models appear to be partly dependent on the
activation of noradrenaline in the BNST (10, 11). The ventral
BNST is highly innervated by noradrenergic neurons and has
very few dopamine or 5-HT terminals (12–14). This means
measured transmitter release from the ventral BNST is directly
attributable to noradrenaline. The ventral BNST is therefore ideal
for studying drug effects on the noradrenergic system ((15–19)).
Here we examined 3,4-CTMP and ethylphenidate on
dopamine and noradrenaline eﬄux in rat brain slices. We
examined dopamine eﬄux as this would help us determined the
likely abuse liability of these drugs. We examined noradrenaline
eﬄux, as a drug that increases noradrenaline levels will likely be
a vasoconstrictor and cause hypertension (20). Thus, these data
also give us some idea of the possible cardiotoxicity of the drug.
METHODS
The two NPS were found in samples from dance club amnesty
bins in London (October—December 2012) and also from
subsequent test purchases from internet sites. They were
FIGURE 1 | Comparison of structures of 3,4-CTMP, ethylphenidate, and
methylphenidate. The chemical structures of 3,4-CTMP (Top) and
ethylphenidate (Middle) are shown, along with that of methylphenidate
(Bottom). Their close structural relationship may be seen.
shown to be pure samples using gas chromatography with
mass spectroscopy (GCMS) and nuclear magnetic resonance
spectroscopy (NMR, data not shown). 3,4-CTMP was found
in one amnesty bin sample while ethylphenidate was found in
27 samples often in combination with other active compounds.
Three samples of each drug were purchased from different
websites and all were found to be essentially pure.
Animals and Dissection
Brain slices used in all experiments were obtained from 8 week
old male Wistar rats (Charles River Laboratories). Animals
were housed 4 per cage, kept on a 12/12-h light/dark cycle
and had food and water available ad libitum. Rats were killed
Frontiers in Psychiatry | www.frontiersin.org 2 May 2018 | Volume 9 | Article 149
Davidson et al. Methylphenidate Analog Legal Highs
FIGURE 2 | Voltammetric technique and voltammograms for exogenous and
endogenous amines. (A) The applied voltage to the carbon electrode (0 to −1
to +1.4 to −1 and back to 0V at 480 V/s which takes 20ms). (B) The
charging current at the electrode in the absence (thick line) and presence (thin
line) of 5µM dopamine; note the dopamine oxidation peak (ox; 0.6 V) where
dopamine releases 2 electrons, creating a Faradaic current. Note also the
reduction peak (red; −0.2 V) where dopamine-o-quinone is reduced back to
dopamine, using 2 electrons. If one subtracts the signal in the presence of
dopamine from the signal in the absence of dopamine one is left with a
voltammogram (C). Voltammograms are also shown for 5µM noradrenaline
(D), stimulated dopamine in the accumbens (E), and stimulated noradrenaline
in the BNST (F). The voltammogram from the apparent ethylphenidate (30µM)
evoked increase in basal accumbens dopamine (see Figure 3C) is shown in
(G), but the voltammogram from the calibration of the electrode in 30µM
ethylphenidate (see Figure 3D) reveals that this drug is electroactive (H). In
each case the oxidation peak is clearly seen. Note that we often get small
non-biological artifacts when the voltage changes direction. Neither
methylphenidate nor 3,4-CTMP were found to be electroactive (data not
shown).
by cervical dislocation, without anesthesia, as anesthetics are
known to affect neurotransmitter levels, particularly monoamine
neurotransmitters. Schedule 1 euthanasia procedures were done
in accordance with the relevant regulations under the UK
Animals (Scientific Procedures) Act 1986.
FIGURE 3 | Raw data from brain slice experiments. In (A,B), after 3 baseline
electrical stimulations (upward arrows), the drug is added (downward arrow)
for 60min while stimulations continue every 5min. In the lower traces (C,D)
there are no electrical stimulations. (A) Shows evoked dopamine efflux in the
nucleus accumbens (NAc) after application of 1µM ethylphenidate (EPH), note
the increase in electrically evoked dopamine. (B) Application of EPH (10µM) in
the bed nucleus of the stria terminalis (BNST), note the increase in stimulated
noradrenaline efflux and the apparent increase in background levels of
transmitter 10min after drug application. (C) Application of 30µM EPH (black
bar = 10min) in the NAc appeared to increase basal dopamine levels (there is
no electrical stimulation in this trace), but on testing 30µM EPH at the carbon
electrode in a calibration it was found that this drug is electroactive (D),
although not nearly as electroactive as dopamine or noradrenaline.
The brain was cut to ∼+3 and −5mm vs. bregma, which
left a block including the nucleus accumbens and bed nucleus
of the stria terminalis (BNST; (21)). Ice-cold aCSF was applied
to the brain throughout the dissection. The posterior surface of
the brain slice was glued to the chuck of a vibratome (Campden
Instruments, Loughborough, UK). The brain and chuck were
submerged in ice-cold aCSF and 400µm coronal slices were
taken to include the nucleus accumbens and BNST, ∼+2.2 to
−0.3 vs. bregma. Sections were then transferred to a slice saver
and suspended on a plastic mesh in aCSF at room temperature,
while continually bubbled with 95%O2/5%CO2.
Chemicals and aCSF
Salts, glucose, haloperidol, yohimbine, GBR12909, and
desipramine were bought from Sigma Aldrich (UK).
Concentrations used were based on previous studies (15, 16).
Artificial cerebrospinal fluid (aCSF) was prepared daily. The
composition of aCSF was: (mM): NaCl (126.0), KCl (2.0),
KH2PO4 (1.4), MgSO4 (2.0), NaHCO3 (26.0), CaCl2 (2.4),
(+)glucose (10.0), bubbled continually with 95% O2/5% CO2.
3,4-dichloromethylphenidate (3,4-CTMP) and ethylphenidate
were initially dissolved in deionized water to 10mM, then diluted
with aCSF.
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FIGURE 4 | Electrically evoked dopamine and noradrenaline: raw data. Each
trace shows the increase in amine level after electrical stimulation (arrow) and
its subsequent reuptake in the absence (left) and presence (right) of the three
psychostimulant drugs. (A) Baseline stimulation in accumbens and (B)
stimulation after 60min of 10µM 3,4-CTMP. (C) Baseline evoked efflux in the
BNST and (D) after 60min of 10µM 3,4-CTMP. (E) Baseline evoked efflux in
the accumbens and (F) after 60min of 10µM ethylphenidate, (G) baseline
evoked efflux in the BNST and (H) after 60min of 10µM ethylphenidate. (I)
Baseline evoked efflux in the accumbens and (J) after 60min of 10µM
methylphenidate, (K) baseline evoked efflux in the BNST and (L) after 60min
of 10µM methylphenidate. All traces are scaled such that the bars denoting
concentration and time are accurate for each trace. The 2 traces in each pair
(A and B; C and D; E and F; G and H; I and J; K and L) were taken from the
same brain slice.
Fast Cyclic Voltammetry
Fast cyclic voltammetry (FCV) is an electrochemical technique
that takes advantage of the electroactive properties of the
monoamine neurotransmitters. It can be used to quantitatively
measure neurotransmitter concentrations, and how these
concentrations differ in the presence of drugs, in real-time
(22). A triangular voltage waveform is applied to a carbon
fiber microelectrode (Figure 4A), which oxidizes dopamine
and noradrenaline at ∼600mV. Calibrations of electrodes in
a known concentration of dopamine or noradrenaline allow
the recorded Faradaic current to be converted into the relevant
neurotransmitter concentration (Figure 4).
Using a Millar Voltammetric Analyser (PD Systems, West
Molesey, UK) we sampled dopamine or noradrenaline levels
at 8Hz. Changes in the sampled signal were captured using
a CED1401 micro3 analog-to-digital converter (Cambridge
Electronic Design (CED), UK), displayed using Spike2 v7.1 data
capturing software.
Electrical Stimulation Protocol
Bipolar tungsten electrodes, with their tips 400µm apart,
were used to locally stimulate either the core of the nucleus
accumbens or the ventral BNST (immediately below the anterior
commissure). In most experiments pseudo-one pulse stimulation
was used to avoid the activation of autoreceptors (23), which
occurs ∼500ms after striatal dopamine release (24, 25). A
train of 10 × 1ms 10mA pulses at 100Hz was applied every
5min using a Neurolog NL800 stimulus isolator (Warner
Instruments, Hamden, CT, USA) under computer control (Spike,
CED). In experiments examining antagonists we used longer
stimulation trains (10 pulses at 10Hz, 900ms train duration).
Longer stimulation trains are useful in examining autoreceptor
antagonists as described above. In the ventral BNST it has been
found that stimulation frequencies of 10 or 20Hz were best to see
autoreceptor antagonist effects (16).
Experimental Protocol
To begin an experiment, slices were transferred from the slice
saver to a laminar flow recording chamber that was supplied
with aCSF via gravity feed, at a rate of 100 ml/h. Slices were
left to equilibrate in the recording chamber for 30min before
starting stimulation of the slice, and the tips of both stimulating
and recording electrodes were placed in the appropriate location
in the brain to record monoamine release in eitherthe nucleus
accumbens or ventral BNST. Recording took place from the
beginning of this 30min period as large spontaneous release
events of dopamine can occur, which is indicative of poor slice
health (26), and on such occasions (5–10%) the experiments were
terminated.
Carbon Fiber Microelectrodes
Carbon fiber microelectrodes were constructed by inserting a
single carbon fiber (Goodfellow Cambridge Ltd, UK), 7µm
in diameter, into a 10 cm long borosilicate glass capillary
tube. The capillary tube was then pulled using an electrode
puller (P-30, Sutter instruments Co, USA) and the exposed
carbon fiber was cut to ∼70µm under a microscope using a
scalpel. Microelectrodes were backfilled with a saline solution
before a length of copper wire was inserted into the end
so it could be connected to the head-stage. A Ag/AgCl
reference electrode and a steel wire auxiliary electrode were
also connected to the head-stage and positioned within the
recording chamber fluid, well away from the slice. Carbon
fiber electrodes were calibrated using 5 or 10µM dopamine
or noradrenaline in aCSF. We also tested 3,4-CTMP and
ethylphenidate in calibrations, to determine whether they
would contribute to our signals (Figures 3C,D). Some drugs
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FIGURE 5 | Effect of methylphenidate, 3,4-CTMP and ethylphenidate in the nucleus accumbens (NAc) and bed nucleus of the stria terminalis (BNST) slice. After 3
baseline electrical stimulations (10 pulses at 100Hz) methylphenidate, 3,4-CTMP or ethylphenidate (EPH) was added at a single concentration (arrow). The drug was
left on for 60min and stimulations continued at 5min intervals. (A) Effect of 3,4-CTMP in the accumbens. (B) Effect of ethylphenidate in the accumbens. (C) Effect of
methylphenidate in the accumbens (D) Comparison of methylphenidate, 3,4-CTMP and ethylphenidate in the accumbens using a two-way ANOVA. Asterisks denote
difference between drugs, (E) Effect of 3,4-CTMP in the BNST. (F) Effect of ethylphenidate in the BNST. (G) Effect of methylphenidate in the BNST. (H) Comparison of
methylphenidate, 3,4-CTMP and ethylphenidate in the BNST using a two-way ANOVA; there was no significant difference between the three drugs, but there was a
significant effect of drug concentrations as denoted by the cross (+). Values are means ± SEM, n = 3–8. *p < 0.05, **p < 0.005, +p < 0.05, ++p < 0.005.
are electroactive themselves and/or can foul electrodes ((27);
Figure 4).
Data Acquisition and Analysis
The current at the carbon electrode was sampled at 50,000Hz
by the computer and stored on one channel using Spike7.
Another channel recorded changes at the dopamine or
noradrenaline oxidation potential (600mV). Peak height
of transmitter eﬄux was calculated. An exponential curve
was also fitted to the reuptake phase of the signal after
each stimulation, using Spike7. This calculated the time-
constants for the exponential decay phase of transmitter
reuptake. The time-constant has been shown to be an
appropriate method to accurately measure monoamine reuptake
(28).
Dopamine or noradrenaline eﬄux was electrically evoked
every 5min and peak height was measured. Aggregate reuptake
data are not shown as on some occasions, especially in the BNST
and most often when drugs were present, the transmitter signal
did not fall to basal levels in an exponential fashion, making
modeling of reuptake difficult. In addition, it has been shown
that peak height correlates well with reuptake effects (28) and
so we only show peak height effects here. Baseline (before drug
application) reuptake time-constants are given in the results
section (Baseline Eﬄux Data). Once three steady baseline eﬄux
events had been obtained, the drug was added for 60min. See
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FIGURE 6 | Characterization of amine released in the BNST and NAc. The
dopamine D2 receptor antagonist, haloperidol (1µM) increased electrically
evoked amine efflux in the accumbens (A) but not the BNST. Similarly, the
noradrenergic α2 receptor antagonist, yohimbine (1µM), increased amine
efflux in the BNST (B) but not the accumbens. The selective dopamine
transporter inhibitor GBR12909 (200 nM) increased amine efflux in the
accumbens (C) but not the BNST while the selective noradrenaline transporter
inhibitor desipramine (50 nM) increased amine levels in the BNST (D) but not
the accumbens. Taken together these data suggest that the amine we are
measuring in the accumbens is dopamine, while that in the ventral BNST is
noradrenaline. Values are means SEM taken at peak drug effect. Data were
analyzed by one-way ANOVA. ***p < 0.001 vs. control; **p < 0.01 vs. control;
*p < 0.05 vs. control. CON, control; HALD, haloperidol; YOH, yohimbine;
GBR, GBR12909; DMI, desipramine. N = 2–8.
Figures 3A,B for example experiments. Data was converted to a
percentage of mean baseline data for statistical analysis.
Statistical analysis of differences between the two drugs
on evoked transmitter release was carried out using two-
way ANOVA with Tukey’s post-hoc multiple comparisons
test (drug X concentration). The data using antagonists or
GBR12909/desipramine were analyzed by one-way AONOVA.
For all analysis we used the peak effect of the drugs at each
concentration. Data is presented as mean± standard error of the
mean (SEM), with a significance level set at p < 0.05.
RESULTS
Baseline Efflux Data
We used local electrical stimulation to evoke both dopamine and
noradrenaline eﬄux in the accumbens and BNST respectively.
Baseline (non-drug) dopamine eﬄux had a peak height of 419 ±
50 nM with decay phase time-constant of 1.23 ± 0.08 s (n = 66).
Baseline noradrenaline eﬄux had a peak height of 169 ± 19 nM
with decay phase time-constant of 1.84 ± 0.16 s (n = 43). See
Figure 2 for example eﬄux events.
Effect of Methylphenidate, 3,4-CTMP, and
Ethylphenidate on Amine Efflux in the
Accumbens
Using a two-way ANOVA we compared the effects of
methylphenidate, 3.4-CTMP and ethylphenidate on electrically
evoked dopamine eﬄux in the accumbens (Figures 5A–D).
There was a main effect of drug [F(2, 62) = 38.929, p < 0.001]
a main effect of drug concentration [F(3, 62) = 43.756, P <
0.001] and a drug X concentration interaction [F(6, 62) = 8.67,
p < 0.01]. Within the methylphenidate treated slices both 1
and 10µM caused a significant increase in dopamine eﬄux (p
< 0.05). Within the 3,4-CTMP treated slices, 100 nM caused
an increase in evoked dopamine levels vs. controls (p < 0.05)
while both 1 and 10µM 3,4-CTMP increased evoked dopamine
levels vs. both control and 100 nM (p < 0.05). Ethylphenidate
did not significantly increase evoked dopamine levels at any
concentration (all p > 0.1).
3,4-CTMP increased dopamine levels to a greater extent than
both methylphenidate and ethylphenidate at 100 nM (p < 0.05
vs. both), 1µM (p < 0.001 vs. both), and 10µM (p < 0.001
vs. ethylphenidate and p < 0.05 vs. methylphenidate) while
methylphenidate increased dopamine levels to a greater extent
than ethylphenidate at 10µM (p < 0.001).
Effect of Methylphenidate, 3,4-CTMP, and
Ethylphenidate on Amine Efflux in the
BNST
Using a two-way ANOVA we compared the effects of
methylphenidate, 3.4-CTMP and ethylphenidate on electrically
evoked noradrenaline eﬄux in the BNST (Figures 5E–H). There
was no main effect of drug [F(2, 54) = 0.0781, p = 0.925] and no
drug X concentration interaction [F(6, 54) = 0.926, p= 0.486] but
there was a main effect of drug concentration [F(3, 54) = 13.933,
P < 0.001, 10µM (p < 0.001), 1µM (p < 0.001), and 0.1µM (p
< 0.05)] all increased evoked noradrenaline eﬄux vs. controls.
Characterization of Amine Efflux in
Accumbens and BNST
Using a one-way ANOVA we compared the effects of haloperidol
and yohimbine in the accumbens and BNST. In the accumbens
there was a significant effect of drug [F(2, 18) = 10.598, p < 0.001;
Figure 6A]. Tukey’s test revealed that amine eﬄux was greater in
the accumbens after haloperidol vs. control (p < 0.001) and was
nearly greater after haloperidol vs. yohimbine (p= 0.056). There
was no significant effect of yohimbine vs. control (p= 0.659).
In the BNST there was also a significant effect of drug [F(2, 9)=
12.477, p < 0.005; Figure 6B]. Yohimbine increased amine eﬄux
vs. haloperidol (p < 0.05) and control (p < 0.01). There was no
significant difference in the effect of haloperidol vs. control (p =
0.999).
Again using a one-way ANOVA we tested the effects of
GBR12909 and desipramine on amine eﬄux in the accumbens
and BNST. In the accumbens there was a significant effect of
drug [F(2, 12) = 20.073, p < 0.001; Figure 6C]. Tukey’s test
revealed that GBR12909 had a significant effect on amine eﬄux
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vs. control (p < 0.001) and desipramine (p < 0.005). There was
no significant effect of desipramine vs. control (p= 876).
In the BNST there was also a significant effect of drug
[F(2, 13) = 6.26, p < 0.005; Figure 6D]. Tukey’s test showed that
desipramine had a greater effect on amine eﬄux vs. control (p <
0.05) and GBR12909 (p < 0.05). There was no effect on amine
eﬄux of GBR12909 vs. control (p= 0.813).
DISCUSSION
The majority of drugs of abuse increase dopamine eﬄux in
the nucleus accumbens (6) by either directly acting on the
dopaminergic terminals or indirectly at the ventral tegmental
area. Both of the NPS studied here are structurally related
to methylphenidate (Ritalin), a treatment for attention deficit
hyperactivity disorder (ADHD). Methylphenidate increases
dopamine levels by blocking the dopamine transporter (DAT)
(29). This potential for abuse has been exploited by legal
high vendors, with methylphenidate’s analogs 3,4-CTMP and
ethylphenidate being offered for sale on many websites.
There is a paucity of published research surrounding 3,4-
CTMP, which was developed and tested in the 1990’s as a
potential treatment for cocaine abuse (30). It was suggested
that some methylphenidate analogs could be used as a potential
substitution therapy in the treatment of cocaine abuse, but
3,4-CTMP did not fall into this category. We have found
3,4-CTMP to dose-dependently increases electrically evoked
dopamine release; 1 and 10µM increased stimulated eﬄux ∼6-
fold. The most likely mechanism of action, through which
3,4-CTMP increases dopamine eﬄux, is by DAT inhibition.
Methylphenidate has been shown to partially block the DAT
(29), and a study using rotating disk electrode voltammetry
in rat striatal suspensions proposed that halogenation of the
aromatic ring of methylphenidate with chlorine increases a
compounds affinity to the DAT (31). In the case of 3,4-
CTMP, this halogenation has occurred twice (at the 3′ and 4′
positions).
Previous work from this lab has examined the effects of
cocaine on accumbens dopamine eﬄux (32, 33). The present data
suggest that 3,4-CTMP is slightly more potent than cocaine at
increasing peak dopamine eﬄux in the rat accumbens slice. The
potential increased potency of 3,4-CTMP vs. cocaine is supported
by the findings of Deutsch et al. (30),who carried out ligand
binding studies in rat striatal preparations to determine 3,4-
CTMP’s ability to inhibit [3H]WIN 35,428, a DAT inhibitor, as
well as to look at the uptake of [3H]dopamine into rat striatal
synaptosomes. They found that 3,4-CTMP was eight times more
potent than methylphenidate at inhibiting WIN,35428 binding.
Drug discrimination studies also suggest that 3,4-CTMP is
much more potent than methylphenidate (34). We have found
3,4-CTMP to increase dopamine levels more potently than
methylphenidate (Figure 5D).
We also found 3,4-CTMP to increase electrically evoked
noradrenaline eﬄux, with 10µMresulting in an∼2-fold increase
in the BNST. We have been unable to find any published data
relating to the effect of 3,4-CTMP on noradrenaline levels,
but methylphenidate does block the noradrenaline transporter
(NET; (35)). Our data suggest that 3,4-CTMP may be have
abuse liability, and that its effects are “cocaine-like” rather than
“amphetamine-like,” as it increases stimulated dopamine release,
but not basal (unstimulated) dopamine levels (36). Similarly,
we found no evidence for methylphenidate or ethylphendiate to
cause reverse transport of dopamine (data not shown).
There is a lack of published research on the effects of
ethylphenidate on monoamine release. Ethylphenidate was first
identified in two overdose victims who had co-administered large
quantities of methylphenidate and ethanol (37), which resulted
in the formation of the previously unknown metabolite of these
two substances, ethylphenidate. The formation of ethylphenidate,
in rat liver preparations incubated with methylphenidate and
ethanol, showed a carboxylase- dependant trans-esterification
process (38) that is thought to be analogous to the formation of
cocaethylene; the metabolite produced with co- administration
of cocaine and ethanol (39). The augmented effects of co-
administration of methylphenidate and ethanol on mouse
locomotion and brain levels of ethylphenidate have been
examined (40, 41). Co-administration of these drugs has also
been tested in humans where ethylphenidate was shown to be
produced along with increased subjective highs (42).
Internet drug fora have provided some useful information
on the effects of ethylphenidate, with some reports suggesting
that it produces a less jittery, more euphoric high than
methylphenidate1,2. Additionally, multiple user reports confirm
euphoria associated with ethylphenidate, as well as less locomotor
stimulation, increased music appreciation and abstract thinking.
We found ethylphenidate to increases electrically evoked
dopamine eﬄux by ∼2-fold. The likely mechanism of
action is by blocking the DAT; the same mechanism of
action as methylphenidate (43). In previous ligand binding
studies, ethylphenidate has been shown to bind to the
dopamine transporter with ∼50% less binding potency than
methylphenidate (29). Ethylphenidate also increased locomotor
activity in mice by 20% less than methylphenidate (44, 45). Taken
together these studies suggest that ethylphenidate is not as potent
as methylphenidate at increasing dopamine levels, consistent
with the present study (Figure 5D).
CONCLUSION
This study explored the neurochemical profile of the NPS
methylphenidate analogs 3,4-CTMP and ethylphenidate as well
as the parent compound methylphenidate. 3,4-CTMP was more
potent than methylphenidate, increasing dopamine release ∼6-
fold, presumably caused by blockade of the DAT. Ethylphenidate
has a weaker effect, modestly increasing stimulated dopamine
release by ∼2-fold. All 3 drugs increased noradrenaline eﬄux
∼2-fold. At the concentrations tested, no drug increased
basal levels of dopamine or noradrenaline, that is, they did
1Drugs Forum – legal high user blog. Available online at: http://www.drugs-forum.
com/forum/showthread.php?t=137752 (Accessed July, 16 2013)
2Drugs Forum: Ethylphenidate. Available at: http://www.drugs-forum.com/
forum/showthread.php?t=134578&page=2 (Accessed June, 05 2013)
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not cause reverse transport as one might expect with an
amphetamine-like drug. The effects of each drug on dopamine
indicate that they have the potential to be addictive, especially
3,4-CTMP.
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